why choose us

First received: November 28, 2022

Clinical Trial: NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor

Study Type: INTERVENTIONAL


Official Title: Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Brief Summary: The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors.The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin.Participants will receive weekly doses of NEROFE and doxorubicin.

Read more